The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 46, Issue 5, 1998, Pages 433-439

  Seaber, Emma J ^a   Peck, Richard W ^a   Smith, Deborah A ^a   Allanson, John ^a   Hefting, Nanco R ^b   Van Lier, Jan J ^b   Sollie, Frans A E ^b   Wemer, Johan ^b   Jonkman, Jan H G ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PRA International USA   (Netherlands)

Author keywords

Bioavailability; Food; Pharmacokinetics; Zolmitriptan

Indexed keywords

SEROTONIN AGONIST; ZOLMITRIPTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ELECTROCARDIOGRAPHY; FEMALE; FOOD INTAKE; HEART RATE; HEMATOLOGY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLES; OXAZOLIDINONES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0031731001     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00809.x     Document Type: Article

References (18)

1. 1D drugs: selectively targeting additional sites ot action. Eur Neurol 1996; 36(Suppl 2): 13-18.
2. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996; 36(Suppl 2): 4-7.
3. 1D agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose range finding study. Neurol 1996; 46: 522-526.
4. Dahlöf C, Diener HC, Goadsby PJ, et al. A multinational, double-blind, placebo-controlled, dose range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995; 35: 292.
5. 1B/1D receptor agoinsts. Neurol 1997; 48(Suppl 3): S21-S24.
6. Rapoport AM, Cady RK, Mathew NT, et al. optimizing the oral dose ot 311C90 in the acute treatment of migraine. Cephalalgia 1995; 15(Suppl 14): 221.
7. 1B/D receptor agonist 311C90 (zolmitriptan): are brain stem sites therapeutic targets in migraine? Pain 1996; 67: 355-359.
8. 1B/1D agonist for migraine. Cephalalgia 1997; 17(Suppl 18): 4-14.
9. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996; 41: 141-147.
10. Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997; 43: 579-587.
11. Lacey LF, Hussey EK, Fowler P. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47: 543-548.
12. Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW. The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug, zolmitriptan (311C90): in healthy volunteers. Br J Clin Pharmacol 1997; 43: 273-281.
13. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 622-651.
14. Houghton LA, Fowler P, Keene ON, Read NW. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in migraine patients. Aliment Pharmacol Ther 1992; 6: 685-691.
15. 1B/1D agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther (in press).
16. 1B/1D agonist: an overview of efficacy. Cephalalgia 1997; 17(Suppl 18): 28-40.
17. Lloyd K. The clinical profile of sumatriptan: safety and tolerability. Eur Neurol 1994; 34(Suppl 2): 40-43.
18. Earl NL. Clinical safety of 311C90: aggregated data from patients and volunteers to date. Eur Neurol 1996; 36(Suppl 2): 8-12.